Fig. 2
Time line of treatment: After assessment and consent, the patients will be enrolled on Day-1 for line placement and research bloods. On Day 0 the patient will undergo apheresis. The Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) will be added to the monocytes and the product will be infused on Day 1. The patient will be monitored for 24 h and released. This schedule will repeat for Cycle 2. Prior to cycle the patient will have disease re-staging based on a CT scan. If the patient is eligible for cycle three, they will receive the product infusion and be released 3 h post infusion